Early M&A: The Secret of Biotech's Success

As a product-focused biotech with two clinical phase cancer compounds ready to out-license, Wilex stands apart from most of its German--and European--peers. It has got to where it is by virtue of tight focus cost control and an early openness to M&A. Wilex now needs to show it can sign the sort of deals it needs to get to the next level.